InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc.

NEWS
Press-Release
July 25, 2017

Moscow, Russia, July 25, 2017InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.

Within the framework of this cooperation, InSysBio provides priority support for ASTEX research. This gives an opportunity to access the best practices of InSysBio in the field of QSP modeling, as well as significantly reduce the time of initiation and execution of projects.

The renewal of the ASTEX agreement once again shows that QSP is a necessary technology to support discovery and development of new drugs in oncology and immuno-oncology therapeutic areas. Such an approach improves all stages of the development: it helps to make strategic GO/ NO GO decisions for research, prioritize targets and compounds, interpret results from animal studies and select optimal design(s) for clinical trials.

"We are very pleased ASTEX has chosen to renew our multi-year Master Service Agreement. It underscores that our partners are satisfied with our services and would like to extend this fruitful and reliable collaboration," said Founder and CEO Oleg Demin, PhD.

September 2020
MoTuWeThFrSaSu
 
1
2
3
4
5
6
7
8
9
1. 09 Sep 2020 14:59 InSysBio to update its Cytocon DB to version 1.2.6.7 InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
10
11
12
13
14
15
16
1. 16 Sep 2020 14:54 InSysBio to take part in ACoP11 InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference
17
18
19
20
21
22
23
1. 23 Sep 2020 10:26 InSysBio announces its collaboration with Genmab The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB) [Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
24
25
26
27
28
29
30
    
Upcoming Events
18.10
InSysBio to participate in ACoP 2025
Tags
Latest News
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling
25.06
InSysBio to announce extension of collaboration with discoveric bio alpha
18.06
InSysBio to publish the new article in CPT: Pharmacometrics & Systems Pharmacology
03.06
InSysBio to present Integration of Cytocon DB and fIVE DB with Heta for QSP modeling